Capital Advisors Inc. OK Sells 21,554 Shares of Novo Nordisk A/S (NYSE:NVO)

Capital Advisors Inc. OK trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 24.4% during the third quarter, Holdings Channel.com reports. The institutional investor owned 66,892 shares of the company’s stock after selling 21,554 shares during the quarter. Capital Advisors Inc. OK’s holdings in Novo Nordisk A/S were worth $7,965,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of NVO. Wealth Enhancement Advisory Services LLC boosted its stake in Novo Nordisk A/S by 14.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after acquiring an additional 37,346 shares in the last quarter. Independence Bank of Kentucky boosted its position in shares of Novo Nordisk A/S by 192.7% during the 3rd quarter. Independence Bank of Kentucky now owns 11,490 shares of the company’s stock worth $1,368,000 after purchasing an additional 7,565 shares in the last quarter. Traynor Capital Management Inc. grew its stake in shares of Novo Nordisk A/S by 3.4% in the 3rd quarter. Traynor Capital Management Inc. now owns 305,404 shares of the company’s stock valued at $36,364,000 after buying an additional 10,019 shares during the period. Cetera Investment Advisers increased its position in Novo Nordisk A/S by 453.3% in the 1st quarter. Cetera Investment Advisers now owns 265,538 shares of the company’s stock valued at $34,095,000 after buying an additional 217,545 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new position in Novo Nordisk A/S during the 2nd quarter worth approximately $1,624,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on NVO. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, October 10th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday. Finally, BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Stock Up 0.0 %

Novo Nordisk A/S stock opened at $111.96 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market cap of $502.42 billion, a PE ratio of 38.34, a price-to-earnings-growth ratio of 1.48 and a beta of 0.42. The firm’s 50-day simple moving average is $124.25 and its 200 day simple moving average is $130.85. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The company had revenue of $9.82 billion during the quarter, compared to analysts’ expectations of $9.91 billion. Research analysts predict that Novo Nordisk A/S will post 3.01 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were given a dividend of $0.5126 per share. The ex-dividend date was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio is currently 24.66%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.